TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Patient's varicose vein symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knowledge, Attitude & Practice (KAP)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pulse Size Ratio (PSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulse Time Delay (PTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: COVID-19 related-mortality
Endpoint domain: Mortality/survival
Primary endpoint: Local tolerability of V0162
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Acute Toxicity > Grade 2 (Skin Toxicity Grade 3 or Above)
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters (AUCtau, Cmax, Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cumulative participant caused violations
Endpoint domain: Adverse events/effects
Primary endpoint: Pre and post procedural anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Summed Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Detection of micro-metastatic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Chronic Disease Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of meningitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: severity of post-operative sore throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with decreased bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to first onset of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of combination therapy on insomnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of TVR and VRT-127394
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of EFV and TDF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longevity of restoration
Endpoint domain: Mortality/survival
Primary endpoint: Liver stiffness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spleen stiffness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stricture resolution of the common bile duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Penetration Aspiration Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Residue Severity Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocal Fold Mobility Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Band 3 Phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microparticle Release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional RBC analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of bleeding during antepartum bleeding attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rate of the screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Yield of albuminuria screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of the screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Difference in skin lesions evaluated by a clinical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient-reported sensory symptoms of chemotherapy-induced peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ophthalmic examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wavefront examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver-related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total blood count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean percentage of blood glucose measurements in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients readmitted to intensive care unit
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute change in forced expiratory volume in one second (FEV1) percent predicted from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of pulmonary exacerbations and those leading to hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annual personal income
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in platelet counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Stenosis of a major coronary artery greater than 25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Endothelial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inter-proximal fluid fluoride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term Safety of Valbenazine
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects with Serum Total Testosterone Levels Between 300 and 1050 ng/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum tolerated dose (MTD) of bevacizumab in combination with sunitinib malate
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Serum Inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cmax of Anaprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of Anaprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Anaprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders Based on Measured Total Testosterone (Cavg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Post-Operative Cognitive Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Emergence Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hydrogen content in parts per million (ppm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Albumin-to-Creatinine Ratio (UCAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: daily total crying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uricolytic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in erythrocyte membrane fatty acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of new bone formed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Microbiological Cure at Urethral or Cervical Sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants able to complete the trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Oxycodone Tablets Used Day 1
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Oxycodone Tablets Used as Reported by Participants 1 Week After Surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Vaginal Dryness Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Standard Uptake Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matrics Consensus Cognitive Battery score (MCCB composite score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCSD Performance-Based Skills Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in composite nasal symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Severe Asthma Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: iron absorption ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Timeline followback (TLFB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aberrant behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conners ADHD Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion who complete >= 1 HIV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion who uptake PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion who complete >= 1 STI test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion to SARS-CoV-2 positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerability of the device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in maximal, active range of motion in extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of introducer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: degree of regional Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of lesions detected by 18F-FSPG PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Obtained and Maintained Competitive Employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent difference in right ventricular volumes (EDV and ESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oral pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PH of Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pressure of Arterial Oxygen molecule (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pressure of Arterial Carbon dioxide molecule (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance of the Malaria/CRP combination test for malaria diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of high levels of C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall survival of 1 year
Endpoint domain: Mortality/survival
Primary endpoint: overall survival of 3 year
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Improvement in Lower Urinary Tract Symptoms (LUTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Restoration of ovarian function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants Who Achieved Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved Endoscopic Response at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved Clinical Remission by CDAI at Week 58
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved Endoscopic Response at Week 58
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance performance assessed by smartphone-based balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance performance assessed by force plates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance performance assessed by Berg balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDF1-α Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Modified Psoriasis Area and Severity Index (mPASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Difference of pain scores using FLACC scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first pass success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients in glycemic target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction of diameter of erythematous lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient's Global Impressions of Improvement (PGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in HDSS score from 3 or 4 to 1 or 2 at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tregs function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NK function/cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spherical equivalent prediction error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to tumor progression (TTP) or death
Endpoint domain: Mortality/survival
Primary endpoint: Pain intensity measured by visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Molecular Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Postpartum maternal anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Breastfeeding self-efficacy level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevention of vision loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete minimal residual disease response rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of symptomatic COVID-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline executive functioning composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Compliance of Auto-CPAP Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: successful sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25-Hydroxyvitamin D Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impulsive Choice Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline Impulsivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miRNA expression over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein expression over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma dDAVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Preload values (GEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: kidney rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: graft lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: accuracy during reaching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective satiety, hunger and desire to eat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of copeptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consonant Nucleus Consonant (CNC) word test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AzBio sentence test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Air-conduction thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of budesonide inhalation suspension
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safe dose for oral 5-ALA administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical bleeding scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with undetectable HCV RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RLS Severity Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney Disease Quality of Life Short Form (KDQOLTM-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: muscular strength recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscular mass recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical performance recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use and preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: UV-induced oxidative stress levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Survivin Gene Expression Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bcl-2 Gene Expression Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bax Gene Expression Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: c-Myc Gene Expression Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caspase-9 Expression Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in B-line score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Distance Walked During the 6-Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Fatigue Score Based on the BTHS-SA
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Neurological disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Categorized Adherence Score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 30-day readmission after discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Seroconversion by ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With ECG Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Cardiac Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Imaging response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision similarity between surgeons
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Alteration in Gut Microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum observed concentration (Cmax) of LC350189 and Colchicine from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) of LC350189 and Colchicine from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes